Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media
- S Skovbjerg1,
- K Roos2,
- S E Holm3,
- E Grahn Håkansson4,
- F Nowrouzian1,
- M Ivarsson5,
- I Adlerberth1,
- A E Wold1
- 1Department of Clinical Bacteriology, University of Gothenburg, Gothenburg, Sweden
- 2ENT Department, Lundby Hospital, Gothenburg, Sweden
- 3Department of Medical Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
- 4ESSUM AB and Institute of Clinical Microbiology, Umeå University, Umeå, Sweden
- 5ENT Department, Sahlgrenska University Hospital, Gothenburg, Sweden
- Susann Skovbjerg, Department of Clinical Bacteriology, Guldhedsgatan 10A, SE-413 46 Gothenburg, Sweden;
- Accepted 29 July 2008
- Published Online First 19 August 2008
Objective: Secretory otitis media (SOM) is characterised by persistent fluid in the middle ear cavity, but the cause is unknown. We investigated the clinical, bacteriological and immunological effects of treatment with probiotic bacteria on SOM.
Design: In this double-blind pilot/preliminary study, 60 children with long-standing SOM (median 6 months) who were scheduled for insertion of tympanostomy tubes were randomised to nasal spray treatment with Streptococcus sanguinis, Lactobacillus rhamnosus or placebo for 10 days before surgery. Clinical evaluation was carried out after 10 days of treatment. Middle ear fluid (MEF) was collected during surgery for quantification of cytokines and detection of bacteria by culture and polymerase chain reaction (PCR). Nasopharyngeal swabs were obtained before treatment and at surgery.
Results: Complete or significant clinical recovery occurred in 7/19 patients treated with S sanguinis compared to 1/17 patients in the placebo group (p<0.05). In the L rhamnosus treatment group, 3/18 patients were cured or much better (p = 0.60 compared with placebo). Spray treatment did not alter the composition of the nasopharyngeal flora or the cytokine pattern observed in the nasopharynx or MEF, except for a higher level of IL-8 found in the nasopharynx of L rhamnosus treated children.
Conclusions: This study shows that spray treatment with S sanguinis may be effective against SOM. The mechanism for the effect remains to be investigated.
Competing interests: KR, SEH and EGH are shareholders in the company Essum AB which produces the probiotic strains used in this clinical study. ESSUM AB also holds the following patent on Lactobacillus rhamnosus (LB21): Lactobacillus-P-SE, 9702083-8. Inventors: E Grahn Håkansson and S Håkansson.
Ethics approval: The study was approved by the Ethics Committee at the University of Gothenburg.
Patient consent: Obtained.